The good and the bad: using C reactive protein to distinguish bacterial from non-bacterial infection among febrile patients in low-resource settings.


Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
05 2020
Historique:
received: 11 02 2020
revised: 14 04 2020
accepted: 17 04 2020
entrez: 30 5 2020
pubmed: 30 5 2020
medline: 25 6 2021
Statut: ppublish

Résumé

C reactive protein (CRP), a marker for the presence of an inflammatory process, is the most extensively studied marker for distinguishing bacterial from non-bacterial infections in febrile patients. A point-of-care test for bacterial infections would be of particular use in low-resource settings where other laboratory diagnostics are not always available, antimicrobial resistance rates are high and bacterial infections such as pneumonia are a leading cause of death. This document summarises evidence on CRP testing for bacterial infections in low-income and middle-income countries (LMICs). With a push for universal health coverage and prevention of antimicrobial resistance, it is important to understand if CRP might be able to do the job. The use of CRP polarised the global health community and the aim of this document is to summarise the 'good and the bad' of CRP in multiple settings in LMICs. In brief, the literature that was reviewed suggests that CRP testing may be beneficial in low-resource settings to improve rational antibiotic use for febrile patients, but the positive predictive value is insufficient to allow it to be used alone as a single tool. CRP testing may be best used as part of a panel of diagnostic tests and algorithms. Further studies in low-resource settings, particularly with regard to impact on antibiotic prescribing and cost-effectiveness of CRP testing, are warranted.

Identifiants

pubmed: 32467355
pii: bmjgh-2020-002396
doi: 10.1136/bmjgh-2020-002396
pmc: PMC7259834
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Biomarkers 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Lancet Glob Health. 2016 Sep;4(9):e633-41
pubmed: 27495137
Br J Gen Pract. 2013 Jul;63(612):e465-71
pubmed: 23834883
PLoS One. 2018 Aug 6;13(8):e0201693
pubmed: 30080904
PLoS Med. 2017 Oct 23;14(10):e1002411
pubmed: 29059253
PLoS One. 2016 Jul 07;11(7):e0158656
pubmed: 27386859
BMC Med. 2016 Oct 6;14(1):131
pubmed: 27716201
Antimicrob Resist Infect Control. 2018 Oct 4;7:119
pubmed: 30323922
Pan Afr Med J. 2017 Jan 31;26:51
pubmed: 28451028
Acta Paediatr. 2009 Nov;98(11):1776-80
pubmed: 19664100
BMC Infect Dis. 2016 Feb 04;16:61
pubmed: 26846919
PLoS One. 2016 Mar 30;11(3):e0152420
pubmed: 27027303
Pediatr Infect Dis J. 2014 Nov;33(11):e273-9
pubmed: 25093971
PLoS One. 2016 Aug 03;11(8):e0160278
pubmed: 27486746
Trans R Soc Trop Med Hyg. 2015 Aug;109(8):535-7
pubmed: 26065879
PLoS Negl Trop Dis. 2018 May 31;12(5):e0006477
pubmed: 29852003
Lancet Glob Health. 2019 Jan;7(1):e119-e131
pubmed: 30554748
Clin Infect Dis. 2017 Jun 15;64(suppl_3):S378-S386
pubmed: 28575375
PLoS One. 2014 Apr 22;9(4):e95868
pubmed: 24755844
Cochrane Database Syst Rev. 2014 Nov 06;(11):CD010130
pubmed: 25374293
Antimicrob Resist Infect Control. 2018 Aug 9;7:98
pubmed: 30116525
BMC Infect Dis. 2015 Nov 11;15:511
pubmed: 26558692
Antibiotics (Basel). 2018 Dec 07;7(4):
pubmed: 30544560
Clin Infect Dis. 2019 Nov 13;69(11):1926-1934
pubmed: 30715250
BMJ. 2017 Mar 29;356:j1054
pubmed: 28356302
Arch Dis Child. 2018 May;103(5):420-426
pubmed: 29269559
PLoS One. 2009 Aug 13;4(8):e6621
pubmed: 19675669
Pediatrics. 2014 Feb;133(2):e363-70
pubmed: 24446443
Clin Infect Dis. 2014 Jun;58(12):1707-15
pubmed: 24696240
Trop Med Int Health. 2017 Mar;22(3):286-293
pubmed: 27935664
Adv Ther. 2015 Jan;32(1):69-85
pubmed: 25620538
Trop Med Int Health. 2012 Sep;17(9):1100-7
pubmed: 22809300
BMJ Open. 2018 Jul 30;8(7):e022250
pubmed: 30061442
Eur J Clin Microbiol Infect Dis. 2016 Jun;35(6):899-902
pubmed: 26936614

Auteurs

Camille Escadafal (C)

Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.

Sandra Incardona (S)

Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.

B Leticia Fernandez-Carballo (BL)

Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.

Sabine Dittrich (S)

Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland sabine.dittrich@finddx.org.
Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH